Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVERMECTIN vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
FDA-approved: Treatment of onchocerciasis (river blindness), strongyloidiasis, and intestinal infections caused by Strongyloides stercoralis.,FDA-approved: Scabies (topical formulation).,Off-label: Treatment of other parasitic infections including ascariasis, trichuriasis, enterobiasis, filariasis, loiasis, and cutaneous larva migrans.,Off-label: Treatment of severe, refractory, or crusted scabies (oral).,Off-label: Used in combination with albendazole for lymphatic filariasis.,Investigational: Used for scabies in institutional settings and for rosacea (topical).
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
Terminal elimination half-life is approximately 18 hours (range 12-24 hours) in healthy adults; prolonged in hepatic impairment.
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Ivermectin is primarily metabolized in the liver by the cytochrome P450 enzyme CYP3A4. It is also a substrate of P-glycoprotein (P-gp).
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Primarily fecal (≥90% as unchanged drug and metabolites); renal excretion is minimal (<1% of dose). Biliary excretion contributes to fecal elimination.
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
Approximately 93% bound to plasma proteins, primarily albumin and possibly alpha-1-acid glycoprotein.
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
Apparent volume of distribution is 3.1-3.5 L/kg (large, indicating extensive tissue distribution including fat and skin).
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
Oral bioavailability is approximately 60-80% (due to extensive first-pass metabolism). Topical bioavailability is negligible (<1% systemic absorption).
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
No dose adjustment required for any degree of renal impairment.
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
Use with caution in severe hepatic impairment; specific Child-Pugh-based dosing not established.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
Weight-based: 150–200 mcg/kg orally once, same as adult; safety for children weighing less than 15 kg not established.
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
No specific dose adjustment; monitor for adverse effects due to potential age-related organ dysfunction.
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
No FDA black box warnings.
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
Severe skin reactions (Mazzotti reaction) when treating onchocerciasis, including pruritus, urticaria, fever, arthralgias, syncope, and lymphadenitis.,Neurological toxicity in high doses or with compromised blood-brain barrier (e.g., due to meningitis, African trypanosomiasis, or Loa loa infection with high microfilarial loads).,Ocular reactions in onchocerciasis: exacerbation of eye lesions, including optic neuritis and chorioretinitis.,Potential for drug interactions with CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) or P-gp inhibitors (e.g., verapamil, cyclosporine), leading to increased ivermectin exposure.,Hypersensitivity reactions.,Use in pregnancy only if clearly needed (data limited).,Not recommended in children under 5 years of age or weighing less than 15 kg.
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
Hypersensitivity to ivermectin or any component of the formulation.,Concurrent use with drugs that inhibit CYP3A4 or P-gp may require caution, but absolute contraindication is rare.,Loa loa infection with high microfilarial loads (risk of severe encephalopathy).
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
Ivermectin should be taken on an empty stomach with water. Administration with food, particularly high-fat meals, can significantly increase absorption (up to 2.5-fold), potentially increasing the risk of adverse effects. Therefore, avoid food for at least 2 hours before and 1 hour after dosing. Grapefruit juice may inhibit CYP3A4 and could theoretically increase ivermectin levels; caution is advised.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
FDA Category C. Animal studies show teratogenicity at high doses. Human data limited; avoid in first trimester unless benefit outweighs risk. No increased malformation risk in second/third trimester from observational studies.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Ivermectin is excreted into breast milk; M/P ratio unknown. Limited human data suggests low levels. Caution in infants weighing <15 kg due to potential CNS effects. Consider temporary cessation of breastfeeding during therapy.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
Pharmacokinetics in pregnancy not well studied. No recommended dose adjustments. Use standard weight-based dosing (150–200 mcg/kg) but avoid in first trimester unless essential.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
Ivermectin is a broad-spectrum antiparasitic agent that causes parasite death by increasing chloride ion conductance in invertebrate nerve and muscle cells. It is the drug of choice for onchocerciasis and strongyloidiasis, and is also used for scabies and head lice. For onchocerciasis, it is given as a single dose of 150 mcg/kg, repeated every 6-12 months. For strongyloidiasis, the recommended dose is 200 mcg/kg daily for 2 days. For crusted scabies, multiple doses (e.g., on days 1, 2, 8, 9) may be required. Note: Ivermectin does not kill adult Onchocerca worms but reduces microfilarial load. Severe adverse effects (Mazzotti reaction) can occur in onchocerciasis due to rapid microfilarial killing. Avoid in patients with Loa loa co-infection due to risk of encephalopathy. Ivermectin is not recommended for children under 15 kg or pregnant women unless benefits outweigh risks. Drug interactions: caution with CYP3A4 inhibitors or inducers; consider dose adjustment with strong inhibitors like ketoconazole.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
Take ivermectin exactly as prescribed, usually on an empty stomach with water.,For strongyloidiasis or scabies, you may need a second dose; complete the full course.,Do not take with food, especially high-fat meals, as they may increase absorption and risk of side effects.,Common side effects include dizziness, pruritus, and gastrointestinal upset.,Report any severe skin rash, swelling, or difficulty breathing immediately.,If being treated for onchocerciasis, you may experience a reaction (fever, itching, joint pain) due to dying parasites; this is usually mild and treatable.,Avoid driving or operating machinery if you experience dizziness or drowsiness.,Inform your doctor if you are pregnant, breastfeeding, or taking other medications.,Do not use ivermectin for COVID-19; it is not approved for viral infections.
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
"Coadministration of ivermectin, a known inhibitor of cytochrome P450 3A4 (CYP3A4), with netupitant, a CYP3A4 substrate, can result in increased systemic exposure to netupitant. This may potentiate netupitant-related adverse effects, such as nausea, fatigue, and QT prolongation, particularly in patients with underlying hepatic impairment or those receiving other QT-prolonging agents."
"Ivermectin is a substrate of CYP3A4 and P-glycoprotein (P-gp), while imatinib is primarily metabolized by CYP3A4 and is also a substrate of P-gp. Concomitant administration of ivermectin may competitively inhibit CYP3A4 and P-gp, reducing the clearance of imatinib and increasing its systemic exposure. This can potentiate imatinib's adverse effects, including hepatotoxicity, fluid retention, and myelosuppression, particularly at high doses."
"Ivermectin is a moderate inhibitor of CYP3A4, the primary enzyme responsible for simeprevir metabolism. Concomitant administration significantly reduces simeprevir clearance, leading to elevated plasma concentrations. This increases the risk of simeprevir-related adverse effects, including hepatotoxicity, QT prolongation, and rash."
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVERMECTIN vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
IVERMECTIN is a Anthelmintic that works by Ivermectin is a macrocyclic lactone that binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx, hyperpolarization, and paralysis of the parasite. It also interacts with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA). In mammals, these channels are largely confined to the central nervous system, but ivermectin does not readily cross the blood-brain barrier, providing a safety margin.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVERMECTIN and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVERMECTIN is: 150–200 mcg/kg orally once, with repeat dose in 2 weeks for strongyloidiasis; for scabies, 200 mcg/kg orally once, repeat in 2 weeks if needed.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVERMECTIN and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVERMECTIN is classified as Category A/B. FDA Category C. Animal studies show teratogenicity at high doses. Human data limited; avoid in first trimester unless benefit outweighs risk. No increased malformation risk in seco. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.